Search Results

You are looking at 1 - 10 of 1,871 items for :

Clear All
Full access

Paul F. Engstrom, Mara G. Bloom, George Daniel Demetri, Phillip G. Febbo, William Goeckeler, Marc Ladanyi, Bryan Loy, Kate Murphy, Michael Nerenberg, Paul Papagni, Mark Robson, Robert W. Sweetman, Sean Tunis, Jessica DeMartino and Jonathan K. Larsen

FDA is considering whether its policy of exercising “enforcement discretion” for LDTs is still appropriate. To provide guidance regarding challenges of molecular testing to health care providers and other stakeholders, NCCN assembled a work group

Full access

Rowena N. Schwartz, Kirby J. Eng, Deborah A. Frieze, Tracy K. Gosselin, Niesha Griffith, Amy Hatfield Seung, Jennifer M. Hinkel, Philip E. Johnson, Shirley A. Johnson, Edward C. Li, Audrea Hotsko Szabatura and Michael K. Wong

The objectives of the NCCN Specialty Pharmacy Task Force included: Describe the current mechanisms of specialty pharmacies as a distribution channel for oncology therapeutic agents and other medications used in drug therapy for individuals with cancer

Full access

Edward C. Li and Jessica DeMartino

practice guidance. The clinical decision-making realm, as NCCN is attuned to, acknowledges the limitations of using available studies and their corresponding data for direct comparison. However, if patient care is to advance, a judgment must be made using

Full access

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke and Sandy Srinivas

several new therapeutic options for patients with advanced RCC. Consequently, the landscape of renal cancer treatment has changed dramatically over recent years and continues to change rapidly. The NCCN Clinical Practice Guidelines in Oncology (NCCN

Full access

Robert W. Carlson, Jonathan K. Larsen, Joan McClure, C. Lyn Fitzgerald, Alan P. Venook, Al B. Benson III and Benjamin O. Anderson

NCCN has developed a comprehensive set of clinical practice guidelines across the continuum of cancer care to assist health care professionals and patients in making clinical decisions. The current set of NCCN Clinical Practice Guidelines in

Full access

Jennifer M. Hinkel

The author has disclosed that she has no financial interest, arrangement, or affiliation with the manufacturers of any products discussed in the article or their competitors. She is an employee of NCCN. References 1. Donabedian

Full access

Phillip G. Febbo, Marc Ladanyi, Kenneth D. Aldape, Angelo M. De Marzo, M. Elizabeth Hammond, Daniel F. Hayes, A. John Iafrate, R. Kate Kelley, Guido Marcucci, Shuji Ogino, William Pao, Dennis C. Sgroi and Marian L. Birkeland

now available that may guide treatment decisions for the most common, deadly malignancies. Given the rapidity with which the field is changing, NCCN assembled a task force to help educate the community with respect to the terminology of contemporary

Full access

Michele Dabrowski, Kenneth Boucher, John H. Ward, Margaret M. Lovell, Angela Sandre, Janet Bloch, Lynne Carlquist, Monica Porter, Larry Norman and Saundra S. Buys

economic analyses . Psychooncology 2004 ; 13 : 837 – 849 . 4. NCCN practice guidelines for the management of psychosocial distress. National Comprehensive Cancer Network . Oncology (Williston Park) 1999 ; 13 : 113 – 147 . 5

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Fidel A. Valea, Emily Wyse, Catheryn M. Yashar, Nicole McMillian and Jillian Scavone

NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that

Full access

George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W.T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott Schuetze, Hema M. Sundar, Jonathan C. Trent and Jeffrey D. Wayne

be useful in predicting response to TKI therapy, identifying new molecular targets for tumor progression, and studying pathogenesis. NCCN GIST Task Force Panel Recommendations for Diagnosing GIST Careful morphologic examination of adequate